Objective: Pigment epithelium-derived factor (PEDF) is a multifunctional protein with neurotrophic and anti-angiogenic properties. More recently it became evident that PEDF is upregulated in patients with type 2 diabetes and also contributes to insulin resistance in mice. During characterization of the secretome of in vitro differentiated human adipocytes by two-dimensional polyacrylamide gel electrophoresis and matrix-assisted laser desorption/ionization-MS, we found that PEDF is one of the most abundant proteins released by adipocytes. The aim of this study was to investigate the regulation and autocrine function of PEDF in human adipocytes and to determine its paracrine effects on human skeletal muscle cells (hSkMC) and human smooth muscle cells (hSMC). Methods and results: Human primary adipocytes secrete 130 ng ml À1 PEDF over 24 h from 1 million cells, which is extremely high as compared with adiponectin, interleukin-6 (IL-6) or IL-8. This release of PEDF is significantly higher than from other primary cells, such as adipose-tissue located macrophages (50-times), hSkMC and hSMC (5-times). PEDF protein expression significantly increases during adipogenesis, which is paralleled by increased PEDF secretion. Furthermore, tumor necrosis factor-a and hypoxia significantly downregulate PEDF protein levels. PEDF secretion was significantly reduced by troglitazone and hypoxia and significantly increased by insulin. Treatment of adipocytes and hSkMC with PEDF induced insulin resistance in adipocytes, skeletal and smooth muscle cells at the level of insulin-stimulated Akt phosphorylation, which was dose dependent and more prominent in adipocytes. Furthermore, inflammatory nuclear factor-kB (NF-kB) signaling was induced by PEDF. In hSMC, PEDF induced proliferation (1.7-fold) and acutely activated proliferative and inflammatory signaling pathways (NF-kB, p38 mitogen-activated protein kinase and mammalian target of rapamycin). Conclusion: PEDF is one of the most abundant adipokines and its secretion is inversely regulated by insulin and hypoxia. PEDF induces insulin resistance in adipocytes and hSkMC and leads to inflammatory signaling in hSMC. Because of these diverse actions, PEDF is a key adipokine, which could have an important role in diabetes and obesity-related disorders.
Introduction
Obesity is increasing dramatically in industrial countries and it is closely associated with the development of chronic diseases including type 2 diabetes and atherosclerosis. 1 It is well established that adipose tissue is not only a storage site for triglycerides but also an important endocrine organ. 2 Adipocytes in expanding fat are capable of releasing a variety of proteins, collectively named adipokines 3 and contributing to a chronic low-grade inflammation state, as well as lipid mediators. One novel adipokine is pigment epitheliumderived factor (PEDF), which is a 50 kDa secreted glycoprotein that belongs to the non-inhibitory serpin group. 4 It was first purified from conditioned media (CM) of human retinal epithelial cells and identified as a neurotrophic factor able to convert retinoblastoma tumor cells into differentiated non-proliferative neurons. 5 A current study showed that PEDF expression in adipose tissue positively correlates with obesity and insulin resistance in mice. 6 This is in accordance with other studies describing a significant correlation between plasma PEDF and obesity in humans, 7, 8 which demonstrates that PEDF secreted from adipose tissue is associated with the metabolic syndrome. The mechanisms how PEDF induces insulin resistance are not fully understood. One factor contributing to insulin resistance is inflammation. PEDF shows proinflammatory signaling in several cell types, 9 and also correlates with inflammation and vascular dysfunction in type 1 diabetics with microvascular complications in comparison with complication-free patients. 10 Using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and matrix-assisted laser desorption/ionizationmass spectroscopy (MALDI-MS) in this study, we report that PEDF is one of the most abundant proteins secreted by in vitro differentiated human adipocytes. In this context, the aim of our study was to get insights into the regulation of PEDF in human adipose tissue and its role in inducing insulin resistance and inflammatory signaling in adipocytes, skeletal muscle and smooth muscle cells, and thereby to provide evidence that PEDF could be a key adipokine, having an important role in diabetes and obesity-related disorders.
Materials and methods

Materials
Reagents for SDS-PAGE were supplied by Amersham Pharmacia Biotech (Braunschweig, Germany) and by Sigma (München, Germany). Polyclonal antibodies anti-phosphomammalian target of rapamycin (mTOR) (Ser2448), antimTOR, anti-phospho-nuclear factor-kB (NF-kB) (P65) (Ser536), anti-NF-kB (P65), anti-p38 mitogen-activated protein kinase, anti-phospho-p38 mitogen-activated protein kinase (Thr180/Tyr182), anti-adipose triglyceride lipase (ATGL) were supplied by Cell Signaling Technology (Frankfurt, Germany). Anti-actin antibodies came from Abcam (Cambridge, UK) and anti-PEDF was obtained from Millipore (Schwalbach, Germany). Anti-laminin receptor (H-141) was obtained from Santa Cruz (Heidelberg, Germany). Horseradish-peroxidase-conjugated goat antirabbit and goat anti-mouse immunoglobulin G antibodies came from Promega (Mannheim, Germany). Collagenase NB4 was obtained from Serva (Heidelberg, Germany). Troglitazone, Cytochalasin B, tumor necrosis factor-a (TNF-a), BSA (fraction V, fatty acid free, low endotoxin) were obtained from Sigma. The Cell Proliferation ELISA (BrdU, chemiluminescent) and Complete protease inhibitor cocktail tablets were from Roche (Mannheim, Germany). Fetal calf serum was supplied by Gibco (Invitrogen, Carlsbad, CA, USA). Human recombinant PEDF was purchased from Millipore (Schwalbach, Germany). The IkB kinase-inhibitor I229 was kindly provided by Sanofi-Avendits (Frankfurt, Germany). 11 All other chemicals were of the highest analytical grade, commercially available and were purchased from Sigma. ) were diluted 1:3 in a buffer containing 25 mM Tris, 4% CHAPS (w/v), 7 M urea and 2 M thiourea and then separated in the first dimension by isoelectric focusing using pH 4-7 linear immobilized pH gradient strips performed on a MultiPhor II electrophoresis unit (GE Healthcare, Freiburg, Germany) and in the second dimension by large format SDS-PAGE (12%), as previously described by us. 15 Directly after electrophoresis, gels were stained with a ruthenium fluorescent stain. 16 Images of protein pattern were acquired by laser scanning of the 2D-gels using blue laser source (457 nm) on a Typhoon 9400 (GE Healthcare) laser scanner and a resolution of 100 mm. Detection of protein spots and calculation of relative spot abundances was carried out automatically using Proteomweaver 4.0 image analysis software (BioRad, Munich, Germany). For the protein identification by MALDI-MS protein spots of interest were excised from the 2D-gels using a Gelpix spot picker (Genetix, Dornach, Germany). After protein digestion with trypsin, extracted peptides were directly applied to a MALDI Prespotted AnchorChip target (Bruker Daltonics, Bremen, Germany) according to the manufacturer's instructions. Subsequently, samples were analyzed in a time-of-flight Ultraflex-Tof/Tof mass spectrometer (Bruker Daltonics). Acquired mass spectra were automatically calibrated and annotated using Compass 1.3 software (Bruker Daltonics). Protein identification via peptide mass fingerprinting was performed on the fly engaging Biotools 3.3 (Bruker Daltonics). As all experiments were performed on primary human adipocytes, MS spectra from each individual spot were used to search a human subset of Swiss-Prot (Sprot_57.8, 20401 protein entries) nonredundant database using Mascot search engine (Version 2.2, Matrix Science, London, UK) in consideration of the following settings: mass tolerance 50 p.p.m., methionine oxidation as variable modification and carbamidomethylation of cysteine as fixed modification. As enzyme, trypsin was selected allowing a maximum of one missed cleavage. Using these settings, a mascot score of 470 was taken as significant (Po0.01). Calculated isoelectric point (pI) and molecular mass data were obtained by Mascot. For peptides matching to different isoforms or multiple members of a protein family, we used the following reporting criteria: The experimental pI and molecular mass taken from the 2D-gels were compared with the theoretical data of the different isoforms/protein members. If no conflicts in molecular mass or pI were found, the isoform/protein member with the highest mascot score was reported. For verifying the results each protein spot was picked and identified from at least three physically different 2D-gels.
Immunoblotting
All cells were treated as indicated and lysed in a buffer containing 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 1% TritonX100, complete protease inhibitor and PhosStop phosphatase inhibitor cocktail (Roche). After incubation for 2 h at 4 1C, the suspension was centrifuged at 10 000 Â g for 15 min. Thereafter, 5 mg protein of hSMC or hSkMC and 10 mg of adipocyte lysates were separated by SDS-PAGE using 10% horizontal gels and transferred to polyvinylidene fluoride filters in a semidry blotting apparatus. 17 Filters were blocked with Tris-buffered saline containing 0.1% Tween and 5% non-fat dry milk and subsequently incubated overnight with a 1:1000 dilution of the appropriate antibodies. After washing, filters were incubated with secondary horseradish-peroxidase-coupled antibody and processed for enhanced chemiluminescence detection using Immobilon horseradish peroxidase substrate (Millipore, Billerica, MA, USA). Signals were visualized and evaluated on a LUMI Imager (Boehringer, Mannheim, Germany) or VersaDoc 4000 MP (BioRad) workstation.
Enzyme-linked immunosorbent assay (ELISA)
PEDF secretion by adipocytes, hSMC, hSkMC and human primary macrophages was determined using ELISA kits purchased from BioVendor GmbH (Heidelberg, Germany).
The assays were performed in duplicates according to the manufacturer's instructions.
Proliferation assay for hSMC
To monitor DNA synthesis, hSMC were seeded in 96-well culture dishes and allowed to attach for 24 h, followed by serum starvation for an additional 24 h period. Cells were then stimulated for 24 h with the different CM in the presence of BrdU (10 mM). The BrdU ELISA Kit from Roche was used to determine proliferation according to the manufacturer's protocol. Signals were visualized and evaluated on a LUMI Imager workstation (Boehringer).
hSMC migration assay Transwell cell migration assay was performed using 24-well transwell chambers with 8 mm pore size polycarbonat membranes (Cell Biolabs Inc., San Diego, CA, USA). hSMC were grown to confluence and serum starved for 24 h. Cell suspension (300 ml) containing 3 Â 10 4 detached cells was added to the upper compartment. Serum-free medium, PEDF, CM or fetal calf serum were placed in the lower compartment (500 ml per well). In control chambers, 2.5 nM cytochalasin B was added to the upper compartment. The cells were then incubated for 18 h. After removal of non-migratory cells, migratory cells were stained and quantified at 570 nm according to the manufacturer's protocol. 
Results
CM from primary human adipocytes contains high amounts of PEDF
We characterized the secretome of in vitro differentiated human adipocytes by 2D-PAGE ( Figure 1a ) and MALDI-MS, and found PEDF to be one of the most abundant proteins in CM (45 ng ml À1 released over 24 h by 350 000 adipocytes). It was identified in 15 spots, which represent 6% of all calculated spot intensities on the gel. Western blot detection of PEDF after 2D-PAGE could reproduce the pattern of this adipokine ( Figure 1b ). Compared with other adipokines measured by us in earlier studies, the concentration of PEDF in CM was about 1800-fold higher than interleukin-6 (IL-6), 800-fold higher than IL-8, 20-fold higher than chemerin and about 7-fold higher than adiponectin (Table 1) . However, in plasma PEDF concentrations are comparable with adiponectin.
PEDF expression and secretion in human primary adipocytes and its regulation
In the light of the high amounts of PEDF found in CM via 2D-PAGE, we analyzed PEDF expression and secretion in human primary adipocytes undergoing differentiation. We found-PEDF protein throughout adipocyte differentiation and increasing during this process with a decrease at later time points (Figure 2a ). In comparison, adiponectin expression was induced by differentiation as expected. PEDF secretion increased transiently during differentiation of adipocytes in parallel to its expression ( Figure 2b ). Additionally, adipocytes at day 14 secreted PEDF continuously over a period of 48 h ( Figure 2c ). As circulating levels of PEDF are high, we tested other primary human cells for their PEDF secretion. As shown in Figure 2d hSkMC, hSMC and human primary macrophages isolated from adipose tissue do secrete PEDF at significantly lower concentrations compared with preadipocytes and adipocytes. Specifically, the secretion of adipose tissue macrophages is very low and it is likely that this cell type does not contribute to the circulating PEDF levels in humans. Prominent regulators of adipocyte secretory activity such as troglitazone, insulin or TNF-a were tested for their ability to influence PEDF expression and secretion in adipocytes. In addition, as hypoxia is now known to occur in adipose tissue of mice [18] [19] [20] and in humans, 21 we also tested whether prominent hypoxia of 1% oxygen has a regulatory function.
We found that PEDF expression is significantly reduced after 24 h incubation with TNF-a or under hypoxia whereas troglitazone and insulin have no effect (Figure 3a) . The concentration of PEDF in CM was significantly reduced after troglitazone and hypoxia treatment, while insulin increased the secretion of PEDF significantly (Figure 3b ). Two proteins, namely ATGL and laminin-R, were postulated to serve also as receptors for PEDF. 22, 23 Preadipocytes and adipocytes express detectable levels of ATGL and laminin-R with higher amounts being detected in the fully differentiated state (Figure 4 ). We also could detect both receptors in hSMC and hSkMC. In human primary macrophages, laminin-R is present, whereas ATGL could not be detected. PEDF 
PEDF action on insulin signaling and inflammatory pathways in adipocytes and hSkMC
Recently it has been put forward that PEDF might be a factor in insulin resistance in mice. 6 Therefore, we tested PEDF in vitro on human primary adipocytes and hSkMC for its effects on insulin signaling and the induction of inflammatory stress signaling. PEDF induces insulin resistance in both adipocytes and hSkMC with more prominent effects on adipocytes (Figures 5a and c) . We also observed a significant induction of NF-kB phosphorylation in adipocytes after 3 h treatment with PEDF and in skeletal muscle cells in a more transient way with a peak after 10 min of PEDF incubation (Figures 5b and d) . The induction of insulin resistance by PEDF in skeletal muscle cells can be prevented by IkB kinaseinhibition (Figure 5e ) making it very probable that PEDF affects insulin-stimulated Akt phosphorylation by increasing serine phosphorylation of IRS-1.
PEDF acutely activates multiple signaling pathways and leads to insulin resistance in hSMC Related to the effects of PEDF on inflammatory signaling and insulin resistance in hSkMC, we further analyzed the impact of PEDF at the level of hSMC. Currently, not much is known about the influence of PEDF on insulin resistance and 
PEDF induces proliferation of hSMC
To investigate the influence of PEDF on early events in the development of atherosclerosis, we assessed its ability to induce proliferation of hSMC. Therefore, DNA synthesis was monitored by determining the incorporation of BrdU using a highly sensitive chemiluminescence immunoassay. As presented in Figure 7a , 10 nM PEDF induced a small but significant increase of hSMC proliferation (1.7-fold). Further, PEDF had no effect on fetal calf serum-stimulated proliferation (data not shown). CM alone, which itself contains about 1 nM PEDF, leads to a robust stimulation of proliferation (three-to four-fold). Adding PEDF to CM has no additional effect on the CM-induced proliferation. As another readout for early events in the development of atherosclerosis, we determined the effect of PEDF on migration of hSMC. Figure 7b shows that PEDF alone has no effect on the migration of hSMC. CM leads to a significant increase of hSMC migration, but the combination of CM and PEDF has no further effect on CM-induced migration.
Discussion
In the context of obesity, adipose tissue as an endocrine organ produces a variety of inflammatory adipokines like IL-6, TNF-a or plasminogen activator inhibitor-1. One novel adipokine is PEDF, which has been shown to be expressed and secreted by adipocytes derived from differentiated human mesenchymal stem cells 24 and 3T3-L1 mouse adipocytes. 6, [25] [26] [27] The expression pattern of PEDF is controversially discussed, as three studies showed a decrease in PEDF mRNA and secretion level during differentiation from preadipocytes to adipocytes in 3T3-L1 cells, [25] [26] [27] whereas one study also from 3T3-L1 cells showed a differentiation PEDF: a high abundant and inflammatory adipokine S Famulla et al dependent increase of PEDF protein levels. 6 Additionally, the latter study revealed PEDF as the most abundant adipokine in supernatants of 3T3-L1 adipocytes. Furthermore, two other studies showed a significant higher expression of PEDF in differentiated human adipocytes compared with preadipocytes. 24, 28 In our system of in vitro differentiated primary human adipocytes, we were able to demonstrate that PEDF is one of the most abundant proteins released by adipocytes, when analyzed by 2D-gel electrophoresis and MALDI-MS. Compared with other adipokines measured by us in earlier studies, PEDF showed a higher concentration than the new adipokine chemerin and even than adiponectin. Furthermore, we showed an increased PEDF protein expression and secretion during differentiation. The role of adipose tissue for PEDF secretion becomes evident since Crowe et al. 6 showed that PEDF expression in adipose tissue positively correlates with obesity and insulin resistance in mice. Furthermore, only modest PEDF secretion from hepatocytes and monocytes was detected, which may indicate that these tissues do not represent the main source for the circulating levels. We also showed in our study that adipose-tissue-derived macrophages secrete only small amounts of PEDF, making it likely that adipocytes are the major contributors to PEDF release from adipose tissue. Additionally two other studies describe a significant correlation between plasma PEDF and obesity in humans 7, 8 pointing to adipose tissue as the main source of PEDF. However, the relevance of the liver contributing to plasma levels of PEDF in humans remains to be elucidated. Little is known about the regulation of PEDF expression and secretion. There is evidence that PEDF protein levels are positively correlated with oxygen tension as it is downregulated in ischemic and hypoxic retinal glial (Müller) cells as well as in anoxic cardiac myocytes. 29, 30 In this study, we could extend the regulation of PEDF by hypoxia to human adipocytes, in which hypoxia represses PEDF expression and release. This repression occurs not in such a prominent manner as in anoxic cardiac myocytes, in which a repression of about 40-50% was observed. 30 However, similar to the effects in retinal glial (Müller) cells, we also observed a reduction of PEDF release of about 15-20% under 1% oxygen. 29 As PEDF is a substrate for metalloproteinase-2 (MMP-2) and MMP-9 and MMPs are upregulated at low oxygen concentrations, reduced levels of PEDF under hypoxia may be because of the post-translational degradation through hypoxia induced MMPs. 31 We also found elevated levels of MMPs after adipocyte treatment with 1% of oxygen (data not shown) so that the downregulation found by us may also underlie a mechanism of degradation of PEDF by MMPs. Additionally, we observed a downregulation of PEDF protein expression under TNF-a treatment without a significant change in PEDF secretion. Yamagishi et al. 32 similarly reported a TNF-a-induced reduction of PEDF mRNA in HUVEC. The mechanism of this reduction is not known until now, but it has been proposed that TNF-a-elicited reactive oxygen species (ROS) generation might be involved, as it could be demonstrated in another study that angiotensin-II-induced ROS could suppress PEDF mRNA levels. 33 It remains to be elucidated whether the reduction of PEDF protein caused by TNF-a treatment occurs by a ROS-dependent mechanism. Additionally, it can be noted that hypoxia and TNF-a are factors that have been shown to regulate some adipokines in a comparable manner as induction of VEGF and IL-6. Similarly adiponectin is inhibited after 24 h treatment of TNF-a and hypoxia. 34, 35 This suggests that PEDF suppression by hypoxia and TNF-a may underlie a common mechanism. We further demonstrate a decrease of PEDF secretion under troglitazone, which has also been described for a number of other adipokines in vivo and in vitro, such as plasminogen activator inhibitor-1, TNF-a or chemerin. [36] [37] [38] Until now it is not known if thiazolidinediones have any regulatory effect in vivo on the circulating levels of PEDF. Hyperinsulinemia has a pivotal role in obesity and type 2 diabetes, and in this study we demonstrate that insulin treatment of adipocytes led to a significant higher release of PEDF by adipocytes. This might reflect one cause of the elevated plasma levels of PEDF found who demonstrated elevated PEDF levels in high-fat diet fed mice, which were obese and also developed a hyperinsulinemic phenotype. It is assumable that not the obese state alone but the combination with hyperinsulinemia caused the observed increase in PEDF serum levels. 6 It should be noted that the divergence between PEDF expression and secretion, as it is observed for troglitazone, TNF-a and insulin may be a question of time course. In the case of TNF-a, PEDF expression is decreased after 24 h, whereas an effect on the secretion of PEDF may only be observable at later time points. PEDF has been described as a multifunctional protein with different functions in diverse cell types and it is assumed that PEDF functions via multiple receptors and ligands. 9 Until now two distinct proteins were suggested to function as receptors for PEDF, namely ATGL and laminin-R. In 2006, Notari et al. 22 identified patatin-like phospholipase domain containing protein-2, also known as ATGL, as a specific receptor for PEDF. There is upcoming evidence that PEDF affects lipolysis in adipose tissue and takes part in the hepatic lipid accumulation depending on ATGL. 6, 39 It is assumed that PEDF not only affects lipid metabolism but also mediates some of its effects like anti-angiogenic and antitumorigenic activities by inducing lipid mediators. 22 The second known receptor of PEDF, laminin-R, was identified in 2009. This non-integrin receptor is involved in processes such as cell adhesion, differentiation, proliferation and migration. 40 All cell types used in the present investigation express both receptors, however, adipose tissue-located macrophages only have low amounts of laminin-R and no ATGL. It is known that PEDF can also affect macrophages as it inhibits lipopolysaccharide-induced IL-12 production in a mice macrophage cell line. 41 Further it induces apoptosis in a human monocytic leukemia cell line (THP-1) as well as in human primary monocyte-derived macrophages in a PPAR-gdependent manner. 42 Until now, it is not known which receptor mediates these effects, but it is assumable that adipocyte-generated PEDF might directly act on adipose tissue located macrophages and is involved in the cross-talk between macrophages and adipocytes. PEDF could be demonstrated to induce insulin resistance in liver and skeletal muscle in rodents in vivo, both after acute and chronic administration. 6 In this study, we show that in primary human adipocytes and skeletal muscle cells, PEDF can also induce insulin resistance and activate inflammatory signaling. In this context, adipocytes are more sensitive toward PEDF than skeletal muscle cells. Human adipocytes show significantly decreased insulinstimulated Akt phosphorylation at 5-10 nM PEDF and exhibit prolonged, significant activation of NF-kB. Differently, PEDF-treated skeletal muscle cells are characterized by a modest transient activation of this inflammatory pathway. It should be noted that the used concentrations of PEDF are up to 10-times higher than in CM but also significantly lower than circulating serum levels of this adipokine. The higher sensitivity of adipocytes toward PEDF could be explained by the significantly higher expression of ATGL and laminin-R as compared with skeletal muscle cells. Obesity is closely correlated to the development of chronic low-grade inflammation diseases, such as atherosclerosis. 1 However, in obesity PEDF serum levels are upregulated and consequently more PEDF is affecting the vessel wall. One major cell type in the vessel wall is represented by smooth muscle cells, which in the development of atherosclerosis proliferate and migrate into intima. In this study, we could show that in addition to adipocytes and hSkMC, PEDF is also contributing to inflammatory signaling in hSMC. This is in accordance with studies showing that PEDF induces inflammatory signaling in different cell types 9 and correlating PEDF levels to inflammation and vascular dysfunction in type 1 diabetics with microvascular complications. 10 In addition, in this study, we could show for the first time that PEDF also leads to insulin resistance in hSMC at the level of Akt phosphorylation. PEDF further leads to a slight, but significant induction of proliferation of hSMC. Yamagishiet al. 43 showed that PEDF by itself had no effect on SMC proliferation but that it inhibits angiotensin II-induced SMC proliferation (1.3-fold) via suppression of ROS generation. However, in our study, we did not observe an anti-proliferative effect, nor with PEDF alone, neither in the combination with CM, which is known to induce ROS production in hSkMC 44 and hSMC (data not shown). CM itself contains 1 nM PEDF. In our experiments, we used 10 nM PEDF, suggesting that PEDF itself is not responsible for the CM-induced proliferation. Treating the cells with rapamycin or an IkB kinase inhibitor, as used by us in a recent study, 11 totally reduced PEDF-induced proliferation to the level of control, suggesting that both mTOR and NF-kB are responsible for the observed proliferative effect of PEDF (data not shown). In accordance to a study from Nakamura et al., we could not observe an effect of PEDF per se on the migration of hSMC. However, Nakamura et al. 45 showed that PEDF could inhibit the PDGF-induced migration of SMC by blocking ROS generation. In our study, we could not detect an inhibitory effect of PEDF on CM-induced migration, despite the fact that CM induced ROS in our cell system. The role of PEDF is discussed controversially. On the one hand, PEDF has been suggested to have a protective role in atherosclerosis because of its anti-inflammatory, antioxidant and anti-thrombotic properties in the vessel wall and platelets. 46 The neuroprotective and anti-angiogenic activities of PEDF make it a promising candidate for a therapeutic agent in the case of proliferative diabetic neuropathy or age-related macular degeneration, where both activities are important for controlling the pathology. PEDF has also emerged as an anti-tumor agent, which is able to act on many different types of tumors. 47 On the other hand, PEDF leads to insulin resistance and inflammatory signaling in several cell types as shown by us and others. 6, 9 These findings point to a yet uncharacterized role of PEDF in the metabolic syndrome, insulin resistance and diabetes.
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In the light of PEDF as a therapeutic target it should be noticed that PEDF could mediate other unexpected secondary effects in different cell types and tissues. The observation that PEDF is secreted in high amounts by adipocytes and its autocrine action demonstrated in this study, raise the question which specific role PEDF may have in adipose tissue. Because of its anti-angiogenic properties PEDF is postulated to have a role in maintaining homeostasis of expanding adipose tissue by inhibiting excessive vascularization. 6 On the other hand, because of the upcoming evidence that PEDF may have a pivotal role in lipolysis, 6, 22, 48 PEDF could be involved in lipid homeostasis of adipose tissue. The autocrine effects described in this study identify PEDF as a novel factor in the induction of adipose tissue inflammation and insulin resistance.
In conclusion, we identified PEDF as one of the most abundant adipokines released by adipocytes concluding adipose tissue represents one of the main sources for circulating levels of PEDF. The different autocrine and paracrine actions mediated by PEDF affecting different cell types and tissues illustrate the complexity of this new adipokine and its role in obesity and obesity-related disorders.
